



International Journal of Current Trends in Pharmaceutical Research

Journal Home Page: www.pharmaresearchlibrary.com/ijctpr



RESEARCH ARTICLE

RP-HPLC Method Development and Validation for Simultaneous Estimation of Montelukast and Fexofenadine Hydrochloride in Bulk and Pharmaceutical Dosage Form

L. Nikhil kumar*¹, Chandan R.S²

¹JSS Academy of Higher Education and Research, Mysore-570015 Karnataka, India.

²Department of Pharmaceutical Chemistry, JSS College of Pharmacy, JSS Academy of Higher Education and Research, Mysore 570015 Karnataka, India.

ABSTRACT

A new method was established for simultaneous estimation of Fexofenadine Hydrochloride Hydrochloride and Montelukast by RP-HPLC method. The chromatographic conditions were successfully developed for the separation of Fexofenadine Hydrochloride and Montelukast by using Xterra C18 5 μ m (4.6*250mm) column, flow rate was 1ml/min, mobile phase ratio was Phosphate buffer (0.05M) pH 4.6: ACN (55:45% v/v) (pH was adjusted with orthophosphoric acid), detection wave length was 255nm. The instrument used was Waters HPLC Auto Sampler, Separation module 2695, PDA Detector 996, Empower-software version-2. The retention times were found to be 2.399mins and 3.907mins. The % purity of Fexofenadine Hydrochloride and Montelukast was found to be 100.7% and 101.4% respectively. The system suitability parameters for Fexofenadine Hydrochloride and Montelukast such as theoretical plates and tailing factor were found to be 1.3, 5117.5 and 1.4, 3877.3 the resolution was found to be 8.0. The analytical method was validated according to ICH guidelines (ICH, Q2 (R1)). The linearity study for Fexofenadine Hydrochloride and Montelukast was found in concentration range of 1 μ g-5 μ g and 100 μ g-500 μ g and correlation coefficient (r²) was found to be 0.999 and 0.999, % mean recovery was found to be 100% and 100.5%, %RSD for repeatability was 0.2 and 0.4, % RSD for intermediate precision was 0.5 and 0.1 respectively. The precision study was precise, robust and repeatable. LOD value was 2.95 and 3.04 and LOQ value was 9.87 and 10 respectively.

Keywords: Fexofenadine Hydrochloride and Montelukast, RP-HPLC method

ARTICLE INFO

Corresponding Author

L. Nikhil kumar
JSS Academy of Higher Education and Research,
Mysore-570015 Karnataka, India.
MS-ID: IJCTPR3782



PAPER QR-CODE

Article History: Received 07 November 2018, Accepted 12 December 2018, Available Online 15 January 2019

Copyright © 2019 L. Nikhil kumar. Production and hosting by Pharma Research Library. All rights reserved.

This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution and reproduction in any medium, provided the original work is properly cited.


Citation: L. Nikhil kumar. RP-HPLC Method Development and Validation for Simultaneous Estimation of Montelukast and Fexofenadine Hydrochloride in Bulk and Pharmaceutical Dosage Form. *Int. J. Curr. Tren. Pharm. Res., Res.*, 2019, 7(1): 31-36.

CONTENTS

| | |
|------------------------------------|----|
| 1. Introduction. | 32 |
| 2. Materials and Methods | 32 |
| 3. Results and Discussion. | 33 |
| 4. Conclusion. | 36 |
| 5. References. | 36 |


1. Introduction

Fexofenadine, sold under the trade name Allegra among others is an antihistamine pharmaceutical drug used in the treatment of allergy symptoms, such as hay fever and urticaria. Therapeutically, fexofenadine is a selective peripheral H1-blocker. Fexofenadine is classified as a second-generation antihistamine because it is less able to pass the blood-brain barrier and cause sedation, compared to first-generation antihistamines. It has also been called a third-generation antihistamine, although there is some controversy associated with the use of the term.



Fexofenadine

Montelukast (trade name Singulair) is a leukotriene receptor antagonist (LTRA) used for the maintenance treatment of asthma and to relieve symptoms of seasonal allergies. Montelukast comes as a tablet, a chewable tablet, and granules to take by mouth. Montelukast is usually taken once a day with or without food.[4] Montelukast is a CysLT1 antagonist; it blocks the action of leukotriene D4 (and secondary ligands LTC4 and LTE4) on the cysteinyl leukotriene receptor CysLT1 in the lungs and bronchial tubes by binding to it. This reduces the bronchoconstriction otherwise caused by the leukotriene and results in less inflammation.



Montelukast

2. Materials and Methods

HPLC Alliance Waters 2695 Waters Empower UV double beam UV 3000 UV Win 5 Lab India Digital weighing pH meter Ultra sonicator Suction pump. Fexofenadine Hydrochloride and Montelukast, Potassium dihydrogen, Acetonitrile, Methanol, Water.

Chromatographic conditions

Trial-5:

Chromatographic conditions:

Column : Xterra C18 5 μ m (4.6*250mm)

Mobile phase ratio: Phosphate buffer (0.05M)

pH 4.6: ACN (55:45% v/v)

Detection wavelength: 255nm

Flow rate : 1ml/min
Injection volume : 20 μ l Column
Temperature : Ambient




Fig. 1: Chromatogram of Trail-5

Preparation of Sample solutions:

For preparation of 50% solution (With respect to target Assay concentration):

Accurately 5mg of Montelukast and 5mg of Faxofenadine Hydrochloride working standard were weighed and transferred into a 10mL and 100ml of clean dry volumetric flask and about 7mL of Diluents was added and sonicated to dissolve it completely and made volume up to the mark with the same solvent. (Stock Solution). Further 3ml and 0.3ml of the above Montelukast and Faxofenadine Hydrochloride stock solution were pipetted into a 10ml volumetric flask and diluted up to the mark with diluent.

For preparation of 100% solution (With respect to target Assay concentration):

Accurately 10mg of Montelukast and 10mg of Faxofenadine Hydrochloride working standard were weighed and transferred into a 10mL, 100ml of clean dry volumetric flask and about 7mL of Diluents was added and sonicated to dissolve it completely and made volume up to the mark with the same solvent. (Stock Solution). Further 3ml and 0.3ml of the above Montelukast and Faxofenadine Hydrochloride stock solution were pipetted into a 10ml volumetric flask and diluted up to the mark with diluent.

For preparation of 150% solution (With respect to target Assay concentration):

Accurately 15mg of Montelukast and 15mg of Faxofenadine Hydrochloride working standard were weighed and transferred into a 10mL and 100ml of clean dry volumetric flask and about 7mL of Diluents was added and sonicated to dissolve it completely and made volume up to the mark with the same solvent. (Stock Solution). Further 3ml and 0.3ml of the above Montelukast and Faxofenadine Hydrochloride stock solution were pipetted into a 10ml volumetric flask and diluted up to the mark with diluent.

Method Validation

Accuracy:

Preparation of standard solution (Faxofenadine Hydrochloride and Montelukast): Accurately weighed 10 mg of Montelukast and 10mg of Faxofenadine Hydrochloride working standard were transferred into a 10mL and 100ml of clean dry volumetric flasks. About 7mL and 70ml of Diluents are added and sonicated to dissolve it completely and made volume up to the mark with the same solvent.

Precision**A) Repeatability:****Preparation of standard stock solution:**

Accurately 10 mg of Montelukast and 10mg of Fexofenadine Hydrochloride working standard were weighed and transferred into a 10mL and 100ml of clean dry volumetric flasks and about 7mL and 70ml of Diluent was added and sonicated to dissolve it completely and made volume up to the mark with the same solvent.

Intermediate Precision (Ruggedness):

To evaluate the intermediate precision (also known as ruggedness) of the method, precision was performed on different days by using different make column of same dimensions.

Specificity

The system suitability for specificity was carried out to determine whether there is any interference of any impurities in retention time of analytical peak. The specificity was performed by injecting blank.

LOD:

LOD's can be calculated based on the standard deviation of the response (SD) and the slope of the calibration curve (S) at levels approximating the LOD according to the formula. The standard deviation of the response can be determined based on the standard deviation of y-intercepts of regression lines.

LOQ:

LOQ's can be calculated based on the standard deviation of the response (SD) and the slope of the calibration curve (S) according to the formula. Again, the standard deviation of the response can be determined based on the standard deviation of y- intercepts of regression lines.

Linearity

Preparation of stock solution:

Accurately 10 tablets were weighed & crushed in mortar and pestle and weight equivalent to 10 mg of Montelukast and Fexofenadine Hydrochloride (marketed formulation) sample were transferred into a 10mL clean dry volumetric flask and about 7mL of Diluent was added and sonicated to dissolve it completely and made volume up to the mark with the same solvent.

Range:

Based on precision, linearity and accuracy data it can be concluded that the assay method is precise, linear and accurate in the range of 1µg-5µg and 100µg- 500µg of Fexofenadine Hydrochloride and Montelukast respectively.

Robustness:





As part of the robustness, deliberate change in the flow rate, mobile phase composition was made to evaluate the impact on the method.

System suitability:

5 mg of Fexofenadine Hydrochloride and 500 mg of Montelukast working standard was accurately weighed and transferred into a 100ml clean dry volumetric flask and add about 20ml of diluent and sonicated to dissolve it completely and make volume up to the mark with the same solvent.

3. Results and Discussion**Linearity:**

International Journal of Current Trends in Pharmaceutical Research

**Fig. 2:** Calibration curve of Montelukast**Fig.3:** Calibration curve of Fexofenadine Hydrochloride**Robustness****Flow Rate:****Fig.4:** Chromatogram for Robustness more flow**Fig. 5:** Chromatogram for Robustness less flow**B) Mobile Phase:**

The Organic composition in the Mobile phase was varied from 70% to 60%. Standard solution 300 µg/ml of Montelukast & 3µg/ml of Fexofenadine Hydrochloride was prepared and analyzed using the varied Mobile phase composition along with the actual mobile phase composition in the method.




Fig. 7: Chromatogram for Robustness more organic




Fig 8: Chromatogram for Robustness less organic

Table 1: Details of Trail-5

| S.No | Peak name | R _t | Area | Height | USP Plate count | USP Tailing | USP Resolution |
|------|----------------------------|----------------|--------|--------|-----------------|-------------|----------------|
| 1 | Faxofenadine Hydrochloride | 2.499 | 945134 | 156429 | 5104 | 1.2 | 7.1 |
| 2 | Montelukast | 3.806 | 112541 | 13839 | 3787 | 1.3 | |

Observation: The chromatogram is perfect with clear separation of components. The peak symmetry and system suitability parameters are within the limits. Hence this method is chosen as optimized one

Table.2: Results for system suitability of Faxofenadin

| Injection | RT(min) | Peak area | TP | TF |
|-----------|---------|-----------|---------|------|
| 1 | 2.5263 | 124652 | 1554.31 | 1.28 |
| 2 | 2.767 | 127376 | 1634.55 | 1.31 |
| 3 | 2.764 | 122803 | 1623.37 | 1.31 |
| 4 | 2.808 | 125382 | 1622.73 | 1.23 |
| 5 | 2.789 | 122153 | 1460.39 | 1.32 |
| 6 | 2.799 | 126345 | 1634.88 | 1.27 |
| Mean | | 123634 | - | - |
| SD | | 631.0 | - | - |
| %RSD | | 0.6 | - | - |

Table.3 Results for system suitability of Montelukast

| Injection | RT(min) | Peak area | TP | TF |
|-----------|---------|-----------|---------|------|
| 1 | 3.901 | 434308 | 4315.31 | 1.17 |
| 2 | 4.016 | 436736 | 4232.73 | 1.17 |
| 3 | 4.012 | 436821 | 4372.54 | 1.17 |
| 4 | 4.140 | 435350 | 4354.17 | 1.17 |
| 5 | 4.077 | 425462 | 4322.22 | 1.17 |
| 6 | 4.056 | 438085 | 4328.19 | 1.18 |
| Mean | | 44531.3 | - | - |
| SD | | 1257.3 | - | - |
| %RSD | | 0.3 | - | - |

Accuracy:

Table 7: Accuracy results of Montelukast

| %Concentration (at specification Level) | Area | Amount added(mg) | Amount found(mg) | % Recovery | Mean Recovery |
|---|---------|------------------|------------------|------------|---------------|
| 50% | 2332744 | 5 | 5.10 | 101.8% | 100.5% |
| 100% | 3132697 | 10 | 9.99 | 99.9% | |
| 150% | 3918997 | 15 | 14.9 | 99.1% | |

Table 8: Accuracy results of Faxofenadine Hydrochloride

| %Concentration (at specification level) | Area | Amount Added (mg) | Amount Found (mg) | % Recovery | Mean Recovery |
|---|---------|-------------------|-------------------|------------|---------------|
| 50% | 353867 | 5 | 5.0 | 101.3% | 100.0% |
| 100% | 4735088 | 10 | 9.94 | 99.4% | |
| 150% | 5911798 | 15 | 14.8 | 99.2% | |

Precision

i) Repeatability

ii) Intermediate precision (Ruggedness)

Table 9: Accuracy results of Faxofenadine Hydrochloride

| Injection | Area |
|---------------------------|---------|
| Injection-1 | 1501417 |
| Injection-2 | 1486940 |
| Injection-3 | 1490656 |
| Injection-4 | 1487329 |
| Injection-5 | 1490384 |
| Average | 1491345 |
| Standard Deviation | 5881.4 |
| %RSD | 0.39 |

| Injection | Area |
|---------------------------|---------|
| Injection-1 | 2235319 |
| Injection-2 | 2240678 |
| Injection-3 | 2249490 |
| Injection-4 | 2245822 |
| Injection-5 | 2251694 |
| Average | 2244601 |
| Standard Deviation | 6656.8 |
| %RSD | 0.32 |

Intermediate precision/Ruggedness**Table 10: Ruggedness results of Montelukast& Faxofenadine Hydrochloride**

| Injection | Area |
|---------------------------|---------|
| Injection-1 | 2194758 |
| Injection-2 | 2195700 |
| Injection-3 | 2196191 |
| Injection-4 | 2195326 |
| Injection-5 | 2200951 |
| Average | 2196585 |
| Standard Deviation | 2496.0 |
| %RSD | 0.11 |

| Injection | Area |
|---------------------------|---------|
| Injection-1 | 1456296 |
| Injection-2 | 1457422 |
| Injection-3 | 1456513 |
| Injection-4 | 1454579 |
| Injection-5 | 1451483 |
| Average | 1455259 |
| Standard Deviation | 2347.6 |
| %RSD | 0.16 |

Table 11: System suitability results For Montelukast (Flow rate)

| S.No | Flow Rate(ml/min) | System suitability results | |
|------|-------------------|----------------------------|-------------|
| | | USP Plate count | USP Tailing |
| 1 | 0.8 | 1748.5 | 1.22 |
| 2 | 1.0 | 1548.2 | 1.2 |
| 3 | 1.2 | 1948.0 | 1.2 |

*Results for actual flow (1.0 ml/min) have been considered from Assay standard.

System suitability results for Faxofenadine Hydrochloride:

Table 12: System suitability results for Faxofenadine Hydrochloride (Flow rate)

| S.No | Flow Rate(ml/min) | System suitability results | |
|------|-------------------|----------------------------|-------------|
| | | USP Plate count | USP Tailing |
| 1 | 0.8 | 883.3 | 1.56 |
| 2 | 1.0 | 1234.0 | 1.1 |
| 3 | 1.2 | 969.2 | 1.6 |

4. Conclusion

A new method was established for simultaneous estimation of Faxofenadine Hydrochloride and Montelukast by RP-HPLC method. The chromatographic conditions were successfully developed for the separation of Faxofenadine Hydrochloride and Montelukast by using Xterra C18 5 μ m (4.6*250mm) column, flow rate was 1ml/min, mobile phase ratio was Phosphate buffer (0.05M) pH 4.6: ACN (55:45% v/v) (pH was adjusted with orthophosphoric acid), detection wave length was 255nm. The instrument used was WATERS HPLC Auto Sampler, Separation module 2695, PDA Detector 996, Empower-software version-2. The retention times were found to be 2.399mins and 3.907mins. The % purity of Faxofenadine Hydrochloride and Montelukast was found to be 100.7% and 101.4% respectively. The system suitability parameters for Faxofenadine Hydrochloride and Montelukast such as theoretical plates and tailing factor were found to be 1.3, 5117.5 and 1.4, 3877.3 the resolution was found to be 8.0. The analytical method was validated according to ICH guidelines (ICH, Q2(R1)). The linearity study for Faxofenadine Hydrochloride and Montelukast was found in concentration range of 1 μ g-5 μ g and 100 μ g-500 μ g and correlation coefficient (r²) was found to be 0.999 and 0.999, % mean recovery was found to be 100% and 100.5%, %RSD for repeatability was 0.2 and 0.4, % RSD for intermediate precision was 0.5 and 0.1 respectively. The precision study was precise, robust, and repeatable. LOD value was 2.95 and 3.04, and LOQ value was 9.87 and 10 respectively. Hence the suggested RP-HPLC method can be used for routine analysis of Faxofenadine Hydrochloride and Montelukast in API, Pharmaceutical dosage form.

5. References

[1] G.R.Chatwal, S.K. Anand, Text book of Instrumental Methods of Chemical Analysis, Himalaya Publishing House, 5th Ed, 2002, p.2.566-2.570.

[2] G.W.Ewing, Text book of Instrumental Methods of Chemical Analysis, Mc Graw-Hill Book Company, 5th Ed, p.375-385.

[3] B.K. Sharma, Textbook of Instrumental Methods of Chemical Analysis, GOEL publishing house, Meerut, 23rd Ed, p.288-289.

[4] G.Vidyasagar, Textbook of Instrumental Methods of Drug Analysis, Pharmamed Press, 2009, p.106-120.

[5] H. H Willard, L. L Merritt, J. A Dean, and F. A Settle, Textbook of Instrumental Methods of Analysis, CBS publishers and distributors, New Delhi, 7th Ed, 1986, p.592-596.

[6] H.H. Tackett, J.A.Cripe, G.Dyson, Positive displacement reciprocating pump fundamentals-power and direct acting types, Proceedings of the twenty-fourth international pump user's symposium, 2008, p.45-58.

[7] D.A.Skoog, F.J.Holler, S.R.Crouch, Textbook of Instrumental Analysis, Brooks/Cole, Cengage Learning India Private Limited, 2007, p.900-906.

[8] R. E. Schirmer, Textbook of Modern Methods of Pharmaceuticals, CRC press, 2nd Ed, P.242-244.

[9] LR.Snyder, JJ Kirkland, LG.Joseph, Practical HPLC Method Development, Wiley Inter Science, New

[10] Ranjith singh, HPLC Method Development and Validation- an Overview, J Pharm. Educ. Res.4 (2013) 26-33.

[11] ICH: Q2B, Analytical Validation – Methodology (1996)